Avenda Health, an AI healthcare company creating the future of personalized prostate cancer care, unveiled the results of a new UCLA study examining the role of AI in identifying tumor margins and predicting the efficacy of focal therapy treatments.
Investigators at the UCLA Health Jonsson Comprehensive Cancer Center have pinpointed a combination immunotherapy treatment that enhances the immune response for people with malignant gliomas, an aggressive type of brain tumor that is fast growing and difficult to treat.
Researchers at The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute said results of a phase II, multi-center clinical trial revealed that a new type of cell therapy is a promising potential treatment option for patients with stage 4 lung cancer who were previously treated but later developed resistance to other therapies.
A phase II trial evaluating setanaxib, Calliditas Therapeutics AB’s lead NOX enzyme inhibitor, in combination with pembrolizumab, in patients with squamous cell carcinoma of the head and neck shows positive topline results.
When cancer breaches the brain, it can be difficult for treatment to follow.
The Wistar Institute assistant professor Filippo Veglia and team have discovered a key mechanism of how glioblastoma suppresses the immune system so that the tumor can grow unimpeded by the body’s defenses.
The phase III KEYNOTE-B21 trial evaluating Keytruda, Merck’s anti-PD-1 therapy, in combination with chemotherapy as adjuvant treatment, with or without radiotherapy, did not meet its primary endpoint of disease-free survival for the treatment of patients with newly diagnosed, high-risk endometrial cancer after surgery with curative intent.
Patients in remission after being treated for a high-risk blood cancer are likely to have better outcomes if no trace of the cancer is detectable before the patients receive donor blood cells.
A national study led by researchers at MD Anderson Cancer Center and the University of New Mexico Comprehensive Cancer Center found major gaps in breast, cervical, and colorectal cancer screening use in Federally Qualified Health Centers in the US, relative to overall screening rates in the country.
The phase III KEYNOTE-811 trial evaluating Keytruda (pembrolizumab), Merck’s anti-PD-1 therapy, in combination with trastuzumab and fluoropyrimidine- and platinum-containing chemotherapy met its dual primary endpoint of overall survival for the first-line treatment of patients with human epidermal growth factor receptor 2-positive locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma.
